Docgo Inc. current report, 08 March 2021

Vollständiges Dokument

Business Context and Reporting Period

Motion Acquisition Corp. filed this Form 8-K on March 8, 2021, reporting entry into a definitive merger agreement with Ambulnz, Inc., doing business as DocGo. Motion is a special purpose acquisition company; DocGo will become a wholly owned subsidiary of the combined public company. The merger was expected to close in the second quarter of 2021, subject to stockholder, regulatory, financing, and other customary conditions.

Transaction Terms and Key Financial Metrics

  • DocGo securityholders were to receive an aggregate of 83,600,000 shares of Motion Class A common stock, reduced by shares reserved for assumed DocGo options and warrants.
  • DocGo securityholders could receive up to 5,000,000 additional contingent shares if specified post-closing stock-price targets of $12.50, $15.00, $18.00, and $21.00 were achieved within defined periods.
  • Motion’s sponsor was required to place 575,000 shares into escrow, subject to release or cancellation based on $12.50 and $15.00 stock-price targets.
  • Motion entered subscription agreements for a private investment in public equity of 12,500,000 shares at $10.00 per share, generating expected gross proceeds of $125 million.
  • The merger agreement required at least $175 million of aggregate cash remaining from Motion’s trust account, permitted proceeds, and the PIPE, after specified deductions, as a condition to DocGo’s closing obligation.
  • Motion also had to maintain at least $5,000,001 of net tangible assets at closing.
  • The filing does not provide DocGo’s revenue, net income, cash flow, margins, debt, cash balance, or liquidity metrics for the reported period. It states that PCAOB-audited financial statements were required and that the transaction could be terminated if reported 2020 revenue materially differed from previously provided unaudited results.

Material Changes Versus the Prior Comparable Period

This is a transaction announcement rather than a periodic earnings filing. The filing does not present a comparable-period income statement, balance sheet, cash-flow statement, or quantified year-over-year operating changes. The material development is the proposed business combination, associated PIPE financing, governance changes, and related shareholder agreements.

Governance, Outlook, Risks, and Unusual Items

  • Following closing, DocGo’s current officers were expected to become officers of the combined company. The board was expected to expand to seven members, with DocGo designating four directors and Motion designating two; Stan Vashovsky was expected to serve as chair.
  • DocGo stockholders holding 72.19% of the expected fully diluted equity of the combined company agreed to six-month lock-ups covering closing and contingent shares.
  • Motion’s sponsor agreed to waive anti-dilution and conversion-price adjustments, allowing its Class B shares to convert one-for-one into common stock at closing.
  • Closing depended on, among other matters, approval by Motion and DocGo stockholders, effectiveness of an SEC registration statement, Nasdaq listing approval, antitrust clearance, New York Department of Health approvals, delivery of PCAOB-audited financial statements, and satisfaction of the minimum cash condition.
  • The agreement could be terminated if the transaction was not completed by November 8, 2021, if required approvals were not obtained, if material breaches or adverse effects occurred, or if the required PCAOB audit was not delivered by June 30, 2021 or contained a qualified opinion.
  • Identified risks included failure or delay of closing, shareholder redemptions and insufficient cash, regulatory or legal proceedings, transaction costs, uncertainty of projections, competition, expansion execution, healthcare regulatory matters, and COVID-19 effects.
  • The filing notes that certain financial information presented by the company was non-GAAP and not compliant with SEC Regulation S-X; the information was expected to be adjusted in the subsequent registration statement.

Most Important Facts to Verify

  • Whether the merger closed and the final capitalization, including shares issued, options, warrants, contingent shares, and sponsor earnout shares.
  • DocGo’s PCAOB-audited 2020 revenue and whether it reconciled with the unaudited figures provided before closing.
  • Final trust-account proceeds, shareholder redemptions, PIPE funding, transaction expenses, and compliance with the $175 million minimum cash condition.
  • DocGo’s audited revenue, profitability, cash flow, debt, liquidity, margins, and reconciliation of non-GAAP measures to GAAP.
  • Whether all stockholder, SEC, Nasdaq, antitrust, and New York Department of Health approvals were obtained.
  • Actual post-closing performance relative to the transaction projections and the stock-price conditions governing contingent and sponsor shares.